Dihexa & Alzheimer's Disease Research

Alzheimer's disease was the original target for Dihexa development. Understanding why researchers pursued this neurotrophic compound for AD, what preclinical evidence showed, and why the clinical translation ultimately failed provides crucial context for anyone evaluating Dihexa's potential.

Why Alzheimer's Was the Original Target

When researchers first synthesized Dihexa in the early 2000s, Alzheimer's disease represented one of the most pressing neurodegenerative challenges. The disease affects approximately 900,000 people living with dementia in the UK, with projections suggesting this will rise to 1.6 million by 2040. This represents an enormous healthcare burden on the NHS and families across the country.

Alzheimer's disease progression involves multiple pathological mechanisms. While amyloid-beta plaques and neurofibrillary tangles are hallmark features, the fundamental problem is synaptic loss and neuronal death. The compound's potential to mimic hepatocyte growth factor (HGF) signalling made it theoretically attractive for addressing this core pathology.

Amyloid-Beta Toxicity and Synaptic Damage

Amyloid-beta (Aβ) is a protein fragment that accumulates abnormally in Alzheimer's brains. While much attention focuses on the plaques it forms, the real damage occurs at the cellular level. Soluble oligomeric forms of Aβ are particularly toxic to synapses—the connection points between neurons.

These oligomers interfere with synaptic plasticity, the ability of synapses to strengthen or weaken over time. This is the molecular basis of learning and memory. Aβ also triggers inflammatory responses, oxidative stress, and mitochondrial dysfunction. The result is progressive loss of synaptic connections, followed by neuronal death.

This is why synaptic loss, rather than plaque burden alone, better predicts cognitive decline in Alzheimer's patients. A person can have significant amyloid pathology but remain cognitively intact if synapses are preserved. Conversely, synaptic loss correlates strongly with dementia severity.

Synaptic Loss as the Key Driver of Dementia

Dihexa's theoretical mechanism focuses on synaptic preservation rather than amyloid reduction. By activating HGF signalling pathways, the compound was proposed to enhance synaptic plasticity and neuronal survival.

This conceptual framework differed from earlier drug development attempts targeting amyloid reduction directly. Many amyloid-targeting drugs showed limited cognitive benefits despite effectively reducing amyloid load. This disconnect suggested that preventing synaptic loss might be more therapeutically relevant than clearing existing plaques.

Dihexa's HGF-mimetic properties offered a neuroprotective approach that could theoretically work alongside or independently of amyloid biology. The compound's ability to cross the blood-brain barrier made it particularly promising for central nervous system effects.

Preclinical Results in Alzheimer's Models

McCoy et al. (2013): Foundation Study

The seminal study by McCoy and colleagues published in 2013 tested Dihexa in cognitive impairment models. They used two paradigms: scopolamine-impaired rats and aged rats with natural cognitive decline. Both models represent relevant Alzheimer's-related pathology.

In scopolamine-treated rats (acute cholinergic deficit model), Dihexa treatment produced dose-dependent improvements in spatial memory tasks. Aged rats similarly showed enhanced performance on cognitive tests. These results provided evidence that the compound could address cognition-relevant neural dysfunction.

McCoy et al. (2013) demonstrated that intranasal Dihexa administration improved cognitive performance in rodent models of dementia-relevant impairment.

Sun et al. (2021): Independent Confirmation

Over eight years later, Sun and colleagues published independent research using APP/PS1 transgenic mice—animals that develop amyloid pathology mimicking human Alzheimer's disease. This study provided valuable independent support for Dihexa's effects.

The transgenic mice showed reduced amyloid burden and improved synaptic markers following Dihexa treatment. This offered evidence from a genetically-driven AD model rather than pharmacologically-induced impairment, strengthening the translational case.

Sun et al. (2021) showed synaptic improvements and reduced amyloid pathology in transgenic Alzheimer's mice treated with Dihexa.

HGF Signalling and Amyloid Protection

Dihexa's proposed mechanism centers on activation of the hepatocyte growth factor receptor, c-Met. HGF signalling promotes neuronal survival, synaptic plasticity, and mitochondrial function. The pathway activates downstream cascades including PI3K/Akt and MAPK/ERK.

In preclinical studies, this signalling appears to provide protection against Aβ-induced toxicity. The mechanism may involve multiple effects: enhanced autophagy (cellular cleanup), reduced neuroinflammation, improved mitochondrial energy metabolism, and enhanced BDNF signalling.

However, it's important to note that c-Met activation also promotes cell growth and proliferation. This dual activity—neuroprotection alongside growth promotion—raised safety concerns during fosgonimeton clinical development.

The Clinical Trial Journey: From Promise to Disappointment

Phase 1: Safety Confirmed

Athira Pharma developed fosgonimeton, an intravenous formulation of Dihexa, for clinical trials. Phase 1 studies in healthy volunteers demonstrated acceptable safety and tolerability. This cleared the path for efficacy testing in Alzheimer's patients.

ACT-AD Trial: Phase 2 Failure

The ACT-AD phase 2 trial enrolled Alzheimer's patients and tested fosgonimeton efficacy on cognitive decline. The trial failed to meet its primary cognitive endpoints. This was the first major setback, suggesting preclinical results might not translate to human disease.

LIFT-AD Trial: Phase 2/3 Termination (September 2024)

Despite the ACT-AD disappointment, Athira advanced to a larger phase 2/3 trial called LIFT-AD. In September 2024, after patient enrollment was complete, the company announced the trial failed to meet its primary cognitive efficacy endpoints. This effectively ended fosgonimeton development for Alzheimer's indication.

The LIFT-AD failure represents a definitive answer: intravenous fosgonimeton does not slow cognitive decline in Alzheimer's disease at the doses tested. This raises fundamental questions about whether the HGF-mimetic mechanism, regardless of formulation, can effectively treat established Alzheimer's pathology.

Why Clinical Translation Failed

Several factors likely contributed to the clinical trials' failure. First, by the time patients enrolled in clinical trials, significant neurodegeneration was already established. Neuroprotection might work better as early prevention rather than late-stage treatment.

Second, the oral bioavailability of Dihexa is limited, and the compound's blood-brain barrier penetration remains uncertain at therapeutic doses in humans. The intravenous formulation (fosgonimeton) was designed to circumvent this, but the results suggest it still failed to achieve sufficient brain levels or duration of action.

Third, Alzheimer's is multifactorial. A single mechanism—even HGF signalling—may be insufficient to address the complex cascade of tau pathology, inflammation, mitochondrial dysfunction, and vascular changes occurring in human disease.

Finally, the preclinical models used relatively young, healthy animals with induced impairment or genetic overexpression of amyloid. Human Alzheimer's disease develops over decades with ageing-related comorbidities and systemic factors not present in animal models.

UK Alzheimer's Statistics and Context

Understanding the scale of Alzheimer's disease in the UK provides context for why treatments like Dihexa attracted attention. Current estimates suggest:

• Approximately 900,000 people living with dementia in the UK (Alzheimer's Society)
• Two-thirds of these have Alzheimer's disease (approximately 600,000 people)
• Projected to rise to 1.6 million by 2040 as the population ages
• Healthcare and social care costs exceed £26 billion annually
• Informal caregiving burden is enormous, affecting family members' employment and wellbeing

This disease burden explains why the NHS and research community continue pursuing disease-modifying treatments, despite repeated setbacks like the LIFT-AD trial failure.

The Retraction Problem and AD Research Implications

One key study supporting Dihexa was retracted from Nature in 2023. This retraction created additional uncertainty about the underlying science. While retraction doesn't eliminate all value from a study's work, it does raise questions about experimental rigor and reproducibility.

For Alzheimer's research specifically, this is significant because the field has experienced multiple false starts. Compounds that appeared promising in preclinical and early clinical data have failed in later-phase trials repeatedly. The retraction adds another layer of uncertainty.

However, the independent confirmation by Sun et al. and the completion of Phase 2/3 clinical trials provides some objectivity. Regardless of publication status, the clinical trials' failure is definitive evidence that fosgonimeton does not benefit Alzheimer's patients at the doses tested.

Future Research Directions

What Would Enable Further Development?

For Dihexa to progress in Alzheimer's research, several conditions would need to be met:

• Earlier intervention: Testing in cognitively normal individuals at high risk, or mild cognitive impairment, rather than established dementia
• Bioavailability optimization: Development of oral formulations with superior brain penetration, or better-tolerated intravenous regimens
• Combination approaches: Testing Dihexa alongside amyloid-targeting drugs or tau-focused therapeutics
• Mechanism refinement: Understanding which aspects of HGF signalling are beneficial versus which drive cancer risk concerns
• Patient stratification: Identifying subgroups (by genetics, biomarker status, disease stage) most likely to respond
• Dose optimization: The LIFT-AD trial used specific doses; alternative dosing strategies haven't been explored

Currently, Athira Pharma has discontinued active Dihexa/fosgonimeton development for Alzheimer's disease. This reflects the clinical evidence and likely the company's strategic pivot away from this indication.

Implications for Other Conditions

While Alzheimer's trials failed, this doesn't necessarily eliminate Dihexa's potential for other neurodegenerative or neurological conditions. Some researchers have hypothesized potential applications in:

• Stroke recovery and neural repair
• Traumatic brain injury
• Parkinson's disease (where synaptic loss is also relevant)
• Age-related cognitive decline (prevention rather than treatment)

However, none of these indications have progressed to clinical trials. The Alzheimer's failure has made future pharmaceutical development of Dihexa difficult to justify from a commercial perspective.

What This Means for Dihexa Users Today

The failure of fosgonimeton in Alzheimer's trials establishes an important fact: a compound that showed promise in animal models and early human studies did not slow cognitive decline in Alzheimer's patients. This is relevant context for anyone considering Dihexa use for cognitive enhancement or age-related cognitive concerns.

It suggests that even well-designed compounds with plausible mechanisms and positive animal data may not translate to human benefit. The reasons are likely multifactorial—disease complexity, bioavailability, formulation, dosing, and patient selection all matter.

For users exploring Dihexa outside pharmaceutical trials, this context highlights the importance of managing expectations and understanding the limited human data available.

Summary

Alzheimer's disease was the original and most plausible target for Dihexa development. The theoretical mechanism—HGF signalling to preserve synapses—was sound. Preclinical evidence in rodent and mouse models was encouraging. However, clinical translation via fosgonimeton failed completely. The September 2024 LIFT-AD trial termination after meeting enrollment demonstrates that this approach, despite decades of development, does not slow Alzheimer's cognitive decline in humans.

This outcome reflects both the inherent difficulty of treating Alzheimer's disease and questions about whether a single neuroprotective mechanism, without addressing amyloid and tau pathology more directly, can be sufficient. For the UK context, where nearly one million people live with dementia, this negative trial is disappointing but contributes valuable knowledge to the field.

Current research interests in Dihexa have largely shifted toward cognitive enhancement in healthy individuals and basic neuroscience applications, reflecting both the failed Alzheimer's trials and the compound's theoretical appeal for other contexts.